Program
Granulocyte Colony-Stimulating Factor
Also written as “G-CSF plus plerixafor”, “G-CSF Plus Plerixafor” and “G-CSF”.
Its studies are mostly in Multiple Myeloma · Lymphoma, Non-Hodgkin · Sarcoma · Infertility, Female · Hot Flashes, led by 6 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 110 open or running | phase 4since Oct 9, 2021 | Feb 11, 2005 | none ahead |
| axaron-bioscience-ag | 10 open or running | phase 2since Aug 18, 2005 | Aug 18, 2005 | none ahead |
| CSL | 10 open or running | phase 1since May 31, 2019 | May 31, 2019 | none ahead |
| MenoGeniX | 10 open or running | phase 1since Jul 30, 2018 | Jul 30, 2018 | none ahead |
| Newlife Fertility Centre | 11 open or running | phase 4since Dec 8, 2023 | Dec 8, 2023 | none ahead |
| Terumo | 10 open or running | no phasesince Sep 23, 2014 | Sep 23, 2014 | none ahead |
Also a collaborator on its studies: AnorMED.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 11, 2005First studies: 2 phase 3 studiesNew to SanofiSanofi · NCT00103662, NCT00103610
- Aug 18, 2005axaron-bioscience-ag's first study: phase 2 study in StrokeNew to axaron-bioscience-agaxaron-bioscience-ag · NCT00132470 · 42 enrolled · Germany
- May 4, 20063 phase 2 studies in Lymphoma, Non-HodgkinSanofi · NCT00322842, NCT00322491, NCT00322387
- Nov 2, 20064 phase 2 studiesSanofi · NCT00396331, NCT00396266, NCT00396201 and 1 more
- Mar 7, 2007Phase 2 study in Lymphoma, Non-HodgkinSanofi · NCT00444912 · 30 enrolled · United States
- Sep 23, 2014Terumo's first study: no phase study in Healthy Apheresis DonorsNew to TerumoTerumo · NCT02253160 · 23 enrolled · United States
- Jul 30, 2018MenoGeniX's first study: phase 1 study in Hot FlashesNew to MenoGeniXMenoGeniX · NCT03640754 · 61 enrolled · United States
- May 31, 2019CSL's first study: phase 1 study in Hidradenitis SuppurativaNew to CSLCSL · NCT03972280 · 39 enrolled · Australia, Denmark, Germany
- Oct 9, 2021Phase 4 study in Autologous Haematopoietic Stem Cell TransplantSanofi · NCT05087212 · 53 enrolled · China
- Dec 8, 2023Newlife Fertility Centre's first study: phase 4 study in InfertilityNew to Newlife Fertility CentreNewlife Fertility Centre · NCT06174298 · 300 planned · Canada
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06174298Infertility · Canada | 4 | Recruiting | Newlife Fertility Centre | Jan 10, 2025 | 300 |
| NCT05087212Autologous Haematopoietic Stem Cell Transplant · China | 4 | Completed | Sanofi | Dec 6, 2022 | 53 |
| NCT03972280Hidradenitis Suppurativa · Australia, Denmark, Germany | 1 | Completed | CSL | Oct 4, 2022 | 39 |
| NCT03640754Hot Flashes · United States | 1 | Completed | MenoGeniX | Jan 21, 2022 | 61 |
| NCT02253160Healthy Apheresis Donors · United States | – | Completed | Terumo | Jan 2015 | 23 |
| NCT00444912Lymphoma, Non-Hodgkin · United States | 2 | Completed | Sanofi | Jun 2009 | 30 |
| NCT00396331Multiple Myeloma · United States | 2 | Completed | Sanofi | Dec 2009 | 100 |
| NCT00396266Multiple Myeloma · Canada | 2 | Completed | Sanofi | Dec 2007 | 22 |
| NCT00396201Hodgkin Disease · United States | 2 | Completed | Sanofi | Oct 2006 | 22 |
| NCT00395967Multiple Myeloma · United States | 2 | Terminated | Sanofi | Jul 2005 | 5 |
| NCT00322842Lymphoma, Non-Hodgkin · Germany | 2 | Completed | Sanofi | Feb 2007 | 35 |
| NCT00322491Lymphoma, Non-Hodgkin · United States | 2 | Completed | Sanofi | Jun 2006 | 49 |
| NCT00322387Lymphoma, Non-Hodgkin · United States | 2 | Completed | Sanofi | Jul 2006 | 40 |
| NCT00132470Stroke · Germany | 2 | Completed | axaron-bioscience-ag | 42 | |
| NCT00103662Multiple Myeloma · United States, Canada, Germany | 3 | Completed | Sanofi | Oct 2006 | 302 |
| NCT00103610Lymphoma, Non-Hodgkin · United States, Canada | 3 | Completed | Sanofi | Jul 2006 | 298 |
How it is read
Names in the registry
- “G-CSF plus plerixafor”, 4 entries
- “G-CSF Plus Plerixafor”, 4 entries
- “G-CSF”, 3 entries
- “Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous”, 2 entries
- “Granulocyte colony-stimulating factor plus plerixafor”, 2 entries
Conditions, from the studies’ own filings
- Multiple Myeloma, 8 studies
- Lymphoma, Non-Hodgkin, 5 studies
- Sarcoma, 1 study
- Infertility, Female, 1 study
- Hot Flashes, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.